MedTrace Logo

AC105 in Patients With Acute Traumatic Spinal Cord Injury

NCT01750684 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-11-06

Study results available
· View outcomes & findings →

Summary

The principal aim of this study was to establish the feasibility of rapid administration, safety, and tolerability of AC105 in patients with acute spinal cord injury.

Conditions

  • Acute Spinal Cord Injury

Interventions

DRUG

AC105

OTHER

Placebo

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • DP Clinical, Inc.

    collaborator INDUSTRY

  • Acorda Therapeutics

    lead INDUSTRY

Principal Investigators

  • Andrew Eisen, MD · Acorda Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-02-28
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01750684 on ClinicalTrials.gov